A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Folinic acid (Primary) ; Ginisortamab (Primary) ; Fluorouracil; Oxaliplatin; Tipiracil/trifluridine
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Male breast cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors UCB Biopharma
Most Recent Events
- 30 Apr 2025 Results(n=32) evaluating primary (safety), secondary (pharmacokinetics), and exploratory (biomarker, efficacy) endpoints from Part A1 (monotherapy dose-optimization) presented at the 116th Annual Meeting of the American Association for Cancer Research.
- 02 May 2024 Status changed from active, no longer recruiting to completed.
- 01 Dec 2023 Planned End Date changed from 13 Feb 2024 to 15 May 2024.